Biotech Values

[palindromy]

Dew, what do you think the path forward and timeline for IDX 899 is likely to be.
Assuming a partnership is done, would they commence a P3 for IDX 899 alone or immediately do a combination study. I haven't followed HIV drugs before, so would appreciate some info on the typical P3 duration and endpoints. Seems to me that not that many patients are required given the clear impact of the drug.